ProCE Banner Activity

Phase III AEGEAN: Analysis of Surgery-Related Outcomes With Neoadjuvant Durvalumab + CT Followed by Adjuvant Durvalumab in Resectable NSCLC

Conference Coverage

Neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab was associated with numerically higher R0 resection rates and no differences in surgical safety outcomes vs placebo plus neoadjuvant chemotherapy among patients with resectable NSCLC.

Released: September 15, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences Inc., and Regeneron Pharmaceuticals, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc